Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
0.005% Latanoprost Gel for Nonsegmental Vitiligo
Official title: Comparison of the Effectiveness Between a Combination of 0.005% Latanoprost Gel With 308 nm Excimer Phototherapy and a Combination of 0.1% Mometasone Furoate Cream With 308 nm Excimer Phototherapy on Repigmentation of Nonsegmental Vitiligo in Children
Status: Opening soon
Description:
Latanoprost, a prostaglandin F2α (PGF2α) analog used for glaucoma treatment, is known to cause iris darkening, hypertrichosis, and periocular skin hyperpigmentation. PGF2α has been shown to stimulate the growth of melanocyte dendrites, increasing dendricity even at low doses, as well as enhancing tyrosinase activity and quantity, thereby promoting repigmentation. Studies on the use of 0.005% latanoprost gel in both children and adults with vitiligo have demonstrated effective repigmentation without reported side effects.
Phase: Phase 2.
What is being studied: drugs — 0.005% latanoprost gel, 0.1% mometasone furoate cream.
Who can take part: ages 10 Years to 17 Years, 10 participants planned.
Enrollment status: the registry has not updated this study since its planned completion date, so its current status is unclear. The study started 01 July 2025 and was due to finish 30 November 2025.
Contact: Safira M Pranata, MD.
Source: ClinicalTrials.gov, NCT07016113 (https://clinicaltrials.gov/study/NCT07016113).
Start date: July 01, 2025
Completion date: November 30, 2025
Organizer: Universitas Padjadjaran
Contact: Safira M Pranata, MD
Tel.: +6281220648003
Email: safira14001@mail.unpad.ac.id
Clinical Trial Alerts
Sign up and be the first to know about updates on this trial.
FAQOther Questions
- Is vitiligo contagious?
Vitiligo is not contagious. This means it cannot be spread from person to person through physical contact, sharing personal items, or any other means of transmission. Vitiligo i...
- What are the best predictors for therapy response in vitiligo?
A fair question. Also a slightly annoying one, because dermatology loves nuance and patients usually want something more like a weather forecast. Still, a few factors do show up...
- Which is better for judging vitiligo — Wood’s lamp or dermoscopy?
A recent study out of India compared the two head-to-head. Both tools correlated fairly well with clinical criteria, but dermoscopy had a slight edge: Wood’s lamp: sensitivity 7...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.